Leukemia
Cyclosporine Modulation of drug resistance with Pravastatin, Etoposide, and Mitoxantrone for Relapsed or Refractory AML (2409)
Cyclosporine Modulation of Drug Resistance in Combination with Pravastatin, Mitoxantrone, and Etoposide for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study
Investigator: Roland Walter, MD; Conditions: Acute Myeloid Leukemia (AML); Status: Recruiting; Study ID: NCT01342887
An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Investigator: Oliver Press, M.D.; Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia; Status: Recruiting; Study ID: NCT01290549
A Phase I Dose Escalation Study of LBH589 in Combination with Imatinib Mesylate for Patients with Chronic Myeloid Leukemia in Cytogenetic Remission with Residual Disease Detectable by Q-PCR
Investigator: Vivian Oehler, MD; Conditions: Chronic Myeloid Leukemia (CML); Status: Recruiting; Study ID: NCT00686218
A Phase 1/2 Study of Vorinostat (Zolinza®) in Combination with Gemtuzumab Ozogamicin (Mylotarg®) and Azacitidine (Vidaza®) in Patients 50 Years of Age and Older with Relapsed/Refractory non-APL Acute Myeloid Leukemia (AML)
Investigator: Roland Walter, MD; Conditions: Acute Myeloid Leukemia (AML); Status: Recruiting; Study ID: NCT00895934
Clofarabine in Combination with Cytarabine (Ara-C) and G-CSF Priming Followed by Infusion of Ex Vivo Expanded Cord Blood Progenitors for Patients with AML
Investigator: Colleen Delaney, MD, MSc; Conditions: Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia; Status: Recruiting; Study ID: NCT01031368
A Phase 1b/2 Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination with Bendamustine vs. Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia
Investigator: John Pagel, MD, PhD; Conditions: Chronic Lymphocytic Leukemia (CLL); Status: Recruiting; Study ID: NCT01188681
A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Relapsed Acute myelogenous Leukemia
Investigator: Fred Appelbaum, MD; Conditions: Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia; Status: Recruiting; Study ID: NCT00840177
A Phase I, Open-Label, Dose-Escalation Study to Evaluate The Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Investigator: Bart Scott, MD; Conditions: Myelodysplastic Syndromes (MDS);, Chronic Myelomonocytic Leukemia (CMML);, Acute Myelogenous Leukemia (AML); Status: Recruiting; Study ID: NCT00528983
A Phase II Study of Epratuzumab (NSC-716711) in Combination with Cytarabine and Clofarabine for Patients with Relapsed or Refractory Ph-Negative Precursor B-cell Acute Lymphoblastic Leukemia (ALL)
Investigator: Fred Appelbaum, MD; Conditions: Acute Lymphoid Leukemia (ALL); Status: Recruiting; Study ID: NCT00945815
Phase 2 Study of the AKT Kinase inhibitor MK-2206 in Patients with Relapsed Refractory Acute Myelogenous Leukemia
Investigator: Roland Walter, MD; Conditions: Acute Myeloid Leukemia (AML);; Status: Recruiting; Study ID: NCT01253447
A Phase I Clinical Study of CWP232291 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Investigator: John Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia (AML); Status: Recruiting; Study ID: NCT01398462
A Phase II Study of Fludarabine (F), Rituximab (R) and Avastin (A) Followed by RA Maintenance Therapy in Patients with Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (CLL)
Investigator: John Pagel, MD, PhD; Conditions: Chronic Lymphoid Leukemia (CLL); Status: Closed; Study ID: NCT00845104
A Study of 131-Tositumomab (Bexxar) Consolidation In Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma In First Remission
Investigator: John M. Pagel, MD, PhD; Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma; Status: Recruiting; Study ID: NCT00476047
A Phase I/II Study of Fludarabine (F), Cyclophosphamide ©), Rituximab ®), and Vorinostat (V) Followed by RV Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small LymphoCtic Lymphoma (SLL)
Investigator: John Pagel, MD, PhD; Conditions: Leukemia, Lymphoma; Status: Recruiting; Study ID: NCT00918723
A Study of Oral Clofarabine Plus Low-dose Cytarabine in Previously Treated AML Patients at Least 60 Years of Age
Investigator: John Pagel, MD; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT00839982
A Phase 1, Open-label, Multicenter Study of MDX-1338 (BMS-936564) in Subjects With Relapsed/Refractory Acute Myelogenous Leukemia
Investigator: Pamela S. Becker, MD, PhD; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT01120457
Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With FLT3-ITD Activating Mutations
Investigator: Elihu Estey, MD; Conditions: Acute Myeloid Leukemia; Status: Closed; Study ID: NCT00989261
A Phase I Trial of Bendamustine/Treanda, Rituxmab, Etoposide, and Carboplatin (TREC) for Patients With Relapsed or Refractory Lymphoid Malignancies
Investigator: Ajay K. Gopal, MD; Conditions: Lymphoma; Status: Recruiting; Study ID: NCT01165112
An Open-Label, Multicenter, Phase Ib Trial of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Investigator: Ajay K. Gopal, MD; Conditions: Chronic Lymphocytic Leukemia; Status: Recruiting; Study ID: NCT01300247
A Phase 1/2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Investigator: John M. Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT01349049
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma
Investigator: John M. Pagel, MD, PhD; Conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma; Status: Recruiting; Study ID: NCT01328626
Join Us On